Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2018-10-31 |
タイトル |
|
|
タイトル |
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma |
言語 |
|
|
言語 |
eng |
DOI |
|
|
|
関連識別子 |
https://doi.org/10.1007/s00280-015-2873-x |
|
|
関連名称 |
10.1007/s00280-015-2873-x |
キーワード |
|
|
主題 |
Ipilimumab, Immune-checkpoint inhibitor, Melanoma Phase II study, Japanese patients |
資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
著者 |
Yamazaki, N.
Kiyohara, Y.
Uhara, H.
Fukushima, S.
Uchi, H.
Shibagaki, N.
Tsutsumida, A.
Yoshikawa, S.
Okuyama, R.
Ito, Y.
Tokudome, T.
|
信州大学研究者総覧へのリンク |
|
|
氏名 |
Okuyama, Ryuhei |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html |
出版者 |
|
|
出版者 |
SPRINGER |
引用 |
|
|
内容記述 |
CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015) |
書誌情報 |
CANCER CHEMOTHERAPY AND PHARMACOLOGY
巻 76,
号 5,
p. 997-1004,
発行日 2015-09-26
|
抄録 |
|
|
内容記述 |
Purpose<br/>Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.<br/>Methods<br/>Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).<br/>Results<br/>Data are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.<br/>Conclusion<br/>Ipilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. |
資源タイプ(コンテンツの種類) |
|
|
内容記述 |
Article |
ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0344-5704 |
書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00598397 |
PubMed |
|
|
|
関連識別子 |
https://www.ncbi.nlm.nih.gov/pubmed/26410424 |
|
|
関連名称 |
26410424 |
権利 |
|
|
権利情報 |
© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000363245800013 |